Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 7, 2016 Category: Endocrinology Source Type: news
APEX: Hopeful Sign Despite Betrixaban Miss for VTE PreventionAPEX: Hopeful Sign Despite Betrixaban Miss for VTE Prevention
The novel oral agent didn't win out over enoxaparin in the trial's primary cohort but did in the larger overall cohort; the later finding was exploratory but convincing nonetheless, say researchers. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news
Betrixaban scores near miss for extended thromboprophylaxis
Extended thromboprophylaxis with the direct factor Xa inhibitor betrixaban just fails to show superiority to standard treatment with enoxaparin in acutely ill medical patients. (Source: MedWire News)
Source: MedWire News - May 31, 2016 Category: Consumer Health News Tags: Thrombosis Source Type: news
Enoxaparin Cost-Effective for Post-Cystectomy VTE Prevention (CME/CE)
(MedPage Today) -- Prophylaxis lowered overall costs, study finds (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 9, 2016 Category: Cardiology Source Type: news
Enoxaparin Sodium Injection (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - March 4, 2016 Category: Drugs & Pharmacology Source Type: news
Teva Bolsters Injectable Portfolio With Launch Of Generic Lovenox And Generic Zyvox In The United States
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, recently announced the launch of the generic equivalent of Lovenox (enoxaparin sodium injection) in seven dosage strengths in the United States (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 23, 2015 Category: Pharmaceuticals Source Type: news
Daiichi Sankyo Begins Phase 3 Study For Edoxaban
Daiichi Sankyo announced that it has initiated enrollment of patients into the multinational Phase III study ENSURE-AF evaluating the safety and efficacy of edoxaban against enoxaparin and warfarin. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 4, 2014 Category: Pharmaceuticals Source Type: news
FDA Underlines Risk of Spinal Procedures on LMW HeparinsFDA Underlines Risk of Spinal Procedures on LMW Heparins
The FDA announced new recommendations aimed at reducing the risk of spinal bleeding with epidural and lumbar puncture procedures among patients taking enoxaparin and other low-molecular-weight heparins. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA updates warning on Sanofi's blood thinner Lovenox
(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding and potential paralysis. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Bleed Risk Falls with Bivalirudin en Route to PCI for STEMIBleed Risk Falls with Bivalirudin en Route to PCI for STEMI
Some will recognize shades of HORIZONS AMI: the gains came from bivalirudin vs heparin or enoxaparin for STEMI, initiated in EUROMAX while patients were in an ambulance en route to a PCI center. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding
The novel anticoagulant can now be considered for both acute and extended treatment of VTE, with a lower risk of major bleeding than standard treatment with enoxaparin and warfarin. (Source: Consultant Live)
Source: Consultant Live - July 18, 2013 Category: Primary Care Source Type: news
Apixaban vs Standard Anticoagulation in Acute VTEApixaban vs Standard Anticoagulation in Acute VTE
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. (Source: theHeart.org)
Source: theHeart.org - July 1, 2013 Category: Cardiology Source Type: news
STREAM Trial Data Supports An Early Fibrinolysis-Based Strategy For Patients With STEMI Who Cannot Undergo Primary PCI
New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin, followed by timely angiography (pharmaco-invasive strategy), compared to patients given primary PCI after the 60-minute window.(1) "In STEMI patients, the most important thing is to re-establish blood supply to the heart... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
NEJM Paper Confirms Value Of Early Fibrinolysis In STEMI
New England Journal of Medicine (NEJM) paper shows prehospital or early fibrinolysis with Metalyse® (tenecteplase) delivers comparable clinical outcomes to gold standard intervention for patients who would not have access to primary PCI within 60 minutes after the first medical contact(b) New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
